

**Patient Group Conflict of Interest Declaration**

1. Did you receive help from outside your patient group to complete this submission? If yes, please detail the help and who provided it. This submission was completed by CLL Patient Advocacy Group in collaboration with Lymphoma Canada.
2. Did you receive help from outside your patient group to collect or analyze data used in this submission? If yes, please detail the help and who provided it. Data collection and analyzing was completed by CLL Patient Advocacy Group in collaboration with Lymphoma Canada.
3. List any companies or organizations that have provided your group with financial payment over the past two years AND who may have direct or indirect interest in the drug under review.

Company
AbbVie Corporation

I hereby certify that I have the authority to disclose all relevant information with respect to any matter involving this patient group with a company, organization, or entity that may place this patient group in a real, potential, or perceived conflict of interest situation.

Name: Deborah Baker    Position: Past-Chair

Patient Group: CLL Patient Advocacy Group    Date: July 21, 2017

### Patient Group Conflict of Interest Declaration

To maintain the objectivity and credibility of the CADTH CDR and pCODR programs, all participants in the drug review processes must disclose any real, potential, or perceived conflicts of interest. This Patient Group Conflict of Interest Declaration is required for participation. Declarations made do not negate or preclude the use of the patient group input. CADTH may contact your group with further questions, as needed.

Did you receive help from outside your patient group to complete this submission? If yes, please detail the help and who provided it. **Yes. This was a joint venture between Lymphoma Foundation Canada (DBA Lymphoma Canada) and CLL-PAG**

1. Did you receive help from outside your patient group to collect or analyze data used in this submission? If yes, please detail the help and who provided it. **Yes, Lymphoma Canada reached out to other patient groups nationally and internationally to collect data. As noted above, both Lymphoma Canada and CLL-PAG shared in the analysis of data.**
2. List any companies or organizations that have provided your group with financial payment over the past two years AND who may have direct or indirect interest in the drug under review.

Company
Roche
AbbVie
Gilead
Janssen
Lundbeck

I hereby certify that I have the authority to disclose all relevant information with respect to any matter involving this patient group with a company, organization, or entity that may place this patient group in a real, potential, or perceived conflict of interest situation.

Name: Robin Markowitz  
 Position: CEO  
 Patient Group: Lymphoma Canada  
 Date: July 21, 2017